Zhao H, Yao W, Min X, Gu K, et al. Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706). J Thorac Oncol 2021 May 22. pii: S1556-0864(21)02177.
PMID: 34033974